Dimethyloxalylglycine improves functional recovery through inhibiting cell apoptosis and enhancing blood-spinal cord barrier repair after spinal cord injury.
10.1016/j.cjtee.2024.10.007
- Author:
Wen HAN
1
,
2
;
Chao-Chao DING
3
;
Jie WEI
4
;
Dan-Dan DAI
3
;
Nan WANG
3
;
Jian-Min REN
3
;
Hai-Lin CHEN
3
;
Ling XIE
2
,
5
Author Information
1. Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, Zhejiang province, China. Electronic address: 18840843748@
2. com.
3. Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, Zhejiang province, China.
4. Clinical Trial Institution, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, Zhejiang province, China.
5. Molecular Pharmacology Research Center, School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang province, China. Electronic address: xieling0612@
- Publication Type:Journal Article
- Keywords:
Blood spinal cord barrier;
Dimethyloxalylglycine;
Endoplasmic reticulum stress;
Hypoxia inducible factor-1α;
Spinal cord injury
- MeSH:
Spinal Cord Injuries/pathology*;
Animals;
Apoptosis/drug effects*;
Amino Acids, Dicarboxylic/therapeutic use*;
Recovery of Function/drug effects*;
Rats;
Rats, Sprague-Dawley;
Hypoxia-Inducible Factor 1, alpha Subunit/metabolism*;
Male;
Spinal Cord/blood supply*
- From:
Chinese Journal of Traumatology
2025;28(5):361-369
- CountryChina
- Language:English
-
Abstract:
PURPOSE:The secondary damage of spinal cord injury (SCI) starts from the collapse of the blood spinal cord barrier (BSCB) to chronic and devastating neurological deficits. Thereby, the retention of the integrity and permeability of BSCB is well-recognized as one of the major therapies to promote functional recovery after SCI. Previous studies have demonstrated that activation of hypoxia inducible factor-1α (HIF-1α) provides anti-apoptosis and neuroprotection in SCI. Endogenous HIF-1α, rapidly degraded by prolylhydroxylase, is insufficient for promoting functional recovery. Dimethyloxalylglycine (DMOG), a highly selective inhibitor of prolylhydroxylase, has been reported to have a positive effect on axon regeneration. However, the roles and underlying mechanisms of DMOG in BSCB restoration remain unclear. Herein, we aim to investigate pathological changes of BSCB restoration in rats with SCI treated by DOMG and evaluate the therapeutic effects of DMOG.
METHODS:The work was performed from 2022 to 2023. In this study, Allen's impact model and human umbilical vein endothelial cells were employed to explore the mechanism of DMOG. In the phenotypic validation experiment, the rats were randomly divided into 3 groups: sham group, SCI group, and SCI + DMOG group (10 rats for each). Histological analysis via Nissl staining, Basso-Beattie-Bresnahan scale, and footprint analysis was used to evaluate the functional recovery after SCI. Western blotting, TUNEL assay, and immunofluorescence staining were employed to exhibit levels of tight junction and adhesion junction of BSCB, HIF-1α, cell apoptosis, and endoplasmic reticulum (ER) stress. The one-way ANOVA test was used for statistical analysis. The difference was considered statistically significant at p < 0.05.
RESULTS:In this study, we observed the expression of HIF-1α reduced in the SCI model. DMOG treatment remarkably augmented HIF-1α level, alleviated endothelial cells apoptosis and disruption of BSCB, and enhanced functional recovery post-SCI. Besides, the administration of DMOG offset the activation of ER stress induced by SCI, but this phenomenon was blocked by tunicamycin (an ER stress activator). Finally, we disclosed that DMOG maintained the integrity and permeability of BSCB by inhibiting ER stress, and inhibition of HIF-1α erased the protection from DMOG.
CONCLUSIONS:Our findings illustrate that the administration of DMOG alleviates the devastation of BSCB and HIF-1α-induced inhibition of ER stress.
